Sarcomatoid Mesothelioma

What Is Sarcomatoid Mesothelioma?

Sarcomatoid mesothelioma is characterized by spindle-shaped cells that resemble those found in sarcomas (cancers of connective tissue). These cells are elongated and often arranged in a haphazard, streaming pattern that differs significantly from the more organized structure of epithelioid cells.

Key characteristics include:

• Spindle-shaped cells with elongated nuclei
• Rapid growth rate compared to other cell types
• Resistance to treatment - generally less responsive to chemotherapy
• Early metastasis - spreads more quickly to distant organs
• Difficult diagnosis - often mistaken for other sarcomas or fibrous tumors

Diagnosis Challenges

Diagnosing sarcomatoid mesothelioma is particularly challenging for several reasons:

Pathological Similarities

Sarcomatoid mesothelioma cells closely resemble:

• Fibrosarcoma
• Malignant fibrous histiocytoma
• Solitary fibrous tumor
• Metastatic renal cell carcinoma
• Sarcomatoid carcinoma of the lung

Immunohistochemistry Markers

Pathologists use special staining techniques to differentiate sarcomatoid mesothelioma from similar tumors. Our detailed immunohistochemistry guide explains these critical diagnostic markers and how pathologists interpret them:

Marker	Sarcomatoid Mesothelioma	Other Sarcomas
Cytokeratin	Usually positive	Usually negative
Calretinin	Often positive	Usually negative
D2-40	May be positive	Usually negative
Desmin	Usually negative	Often positive

Prognosis and Survival Rates

Sarcomatoid mesothelioma has the poorest prognosis of all cell types, primarily due to its aggressive nature and resistance to treatment.

Survival Statistics

• Median survival: Approximately 6 months without treatment
• With treatment: 8-12 months on average
• 1-year survival rate: Approximately 20%
• 5-year survival rate: Less than 5%

However, these are statistics, not destinies. Individual outcomes vary based on:

• Stage at diagnosis
• Age and overall health
• Whether surgery is possible
• Response to chemotherapy
• Access to clinical trials

Treatment Options

Treating sarcomatoid mesothelioma presents unique challenges, but options do exist:

Surgery

Surgical options are limited because sarcomatoid tumors often:

• Spread extensively before diagnosis
• Invade surrounding tissues aggressively
• Metastasize to distant sites early

However, in rare cases where the disease is caught early and is localized, procedures like:

• Pleurectomy/Decortication (P/D): Removal of the pleura and visible tumors
• Extrapleural Pneumonectomy (EPP): Removal of the lung, pleura, and surrounding tissue

May be considered for carefully selected patients.

Chemotherapy

Sarcomatoid mesothelioma is generally less responsive to chemotherapy than epithelioid types, but it remains a standard treatment:

• Pemetrexed + Cisplatin: Standard first-line regimen
• Carboplatin: Alternative for patients who cannot tolerate cisplatin
• Gemcitabine: Sometimes used in combination or as second-line

Response rates are lower (typically 10-15% vs. 40% for epithelioid), but some patients do benefit.

Radiation Therapy

Radiation may be used for:

• Palliation of pain and symptoms
• Preventing recurrence after surgery
• Treating isolated metastases

Immunotherapy

Emerging as a promising option for sarcomatoid mesothelioma:

• Checkpoint inhibitors (pembrolizumab, nivolumab) have shown activity
• Clinical trials exploring combination immunotherapy approaches for improved outcomes
• Some patients with sarcomatoid disease have achieved durable responses

Clinical Trials

Given the limited effectiveness of standard treatments, clinical trials may offer the best hope:

• Novel chemotherapy combinations
• Immunotherapy approaches, including combinations for aggressive sarcomatoid tumors
• Targeted therapies based on tumor marker and genetic profiling
• Gene therapy studies

Biphasic Mesothelioma with Sarcomatoid Component

Biphasic mesothelioma contains both epithelioid and sarcomatoid cells. The prognosis and treatment approach depend on the ratio:

• Epithelioid-dominant biphasic: Better prognosis, more treatment-responsive
• Sarcomatoid-dominant biphasic: Behaves more like pure sarcomatoid

When sarcomatoid cells comprise more than 50% of the tumor, the prognosis approaches that of pure sarcomatoid mesothelioma. Understanding your pathology report is crucial for determining cell ratios and treatment direction. Tumor marker analysis can also help guide treatment decisions.

Living with Sarcomatoid Mesothelioma

While the statistics are daunting, focusing on quality of life and accessing all available resources is important:

Palliative Care

Palliative care specialists can help manage:

• Pain
• Shortness of breath
• Fatigue
• Emotional distress

Early integration of palliative care can significantly improve quality of life.

Support Resources

• Mesothelioma support groups: Connecting with others who understand
• Mental health counseling: For patients and caregivers
• Spiritual care: If meaningful to the patient
• Practical support: Home health, respite care

Legal Options

Given the aggressive nature of sarcomatoid mesothelioma, pursuing legal action promptly is important:

• Compensation may be available through asbestos trust funds
• Lawsuits may result in settlements or verdicts
• Veterans may be eligible for VA benefits
• Expedited case handling may be available for terminal diagnoses

Research and Hope

While sarcomatoid mesothelioma presents significant challenges, research continues:

• Understanding the molecular biology of sarcomatoid transformation
• Developing targeted therapies
• Improving immunotherapy approaches
• Exploring combination treatments

Every advancement in mesothelioma treatment potentially benefits patients with sarcomatoid disease.